glutathione peroxidase 4 Characterization of a patient-derived variant of GPX4 for precision therapy BSA Free (NBP2 Selective Small-Molecule Activator of Patient-Derived

The Journal of Clinical Endocrinology and Metabolism

none- All patients with gout and CKD should receive chronic treatment aiming to achieve UA levels below 6 mg/dL (5 mg/dL in the case of tophaceous gout)

31.6% of cagrilintide participants lost 15% or more of body weight, against 4.7% on placebo

10.3389/fpls.2016.01109 110 McGoldrickS.O'SullivanS

Such performance scores when labelling emotions in odour stand in contrast with comparable performance levels for facial expressions: often over 80% in tests where judges see faces from their own population, despite there usually being twice as many incorrect alternatives than in odour studies (Ekman et al., Reference Ekman, Friesen, O'Sullivan, Chan, Diacoyanni-Tarlatzis, Heider and Tzavaras1987